Try Alerts Free   |   Login
Health Care › Services-Commercial Physical And Biological Research

SRNE Price Correlated With Financials For Sorrento Therapeutics

Free historical financial statements for Sorrento Therapeutics Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 40 quarters since 2012. Compare with SRNE stock chart to see long term trends.

SRNE Stock Compared to Quarterly

SRNE Income Statement

Revenue, Net:13076000
Revenue Per Share:0.0382
Research & Development Expense:59135000
Total Operating Expenses:127685000
Operating Income:-90636000
Income Taxes:-33055000
Net Income:-144954000
Earnings Per Share, Basic:-0.49
Shares Outstanding, Basic Avg:342335102

SRNE Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:2859000
Net Cash from Operations:-72137000
Net Cash from Operations Per Share:-0.2107
Net Cash from Financing Activities:70857000
Property, Plant & Equipment Purchases:2209000
Purchases of Businesses, Net of Cash:null
Net Cash from Investing Activities:-2205000
Net Change in Cash & Equivalents:-3485000

SRNE Balance Sheet

Cash and Cash Equivalents:36665000
Short-Term Investments:90217000
Accounts Receivable, Net:18715000
Inventories:8106000
Total Current Assets:172989000
Property, Plant & Equipment, Net:41325000
Total Assets:694818000
Accounts Payable:27414000
Current Portion of Long-Term Debt:31980000
Total Short-Term Liabilities:139453000
Long Term Debt, Non-Current Portion:110627000
Total Liabilities:616689000

Insider Trading

 
Change
Value
Transaction
SEC Form 4
Ji Henry   President, CEO and Chairman of the Board of Directors
10,000 sh at $1
$13,999
Buy

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Blackrock Inc.
22,034,889 sh
259,024 sh
1%
$51,341
-$49,917
Vanguard Group Inc
15,901,385 sh
208,655 sh
1%
$37,051
-$35,920
Geode Capital Management, LLC
4,986,433 sh
-314,823 sh
-6%
$11,618
-$13,032
JPMorgan Chase & Co
3,298,099 sh
-276,218 sh
-8%
$7,683
-$8,938
Morgan Stanley
3,281,214 sh
2,367,713 sh
259%
$7,645
$3,398
Northern Trust Corp
2,816,938 sh
-128,500 sh
-4%
$6,563
-$7,133
UBS Group Ag
2,480,761 sh
1,631,874 sh
192%
$5,780
$1,833
Rafferty Asset Management, LLC
2,470,682 sh
1,620,162 sh
190%
$5,757
$1,802
Charles Schwab Investment Management Inc
2,201,687 sh
58,593 sh
3%
$5,130
-$4,836
Bank Of New York Mellon Corp
985,502 sh
27,241 sh
3%
$2,297
-$2,158
Mirae Asset Global Investments Co., Ltd.
905,847 sh
-149,396 sh
-14%
$2,111
-$2,796
Swiss National Bank
688,100 sh
64,900 sh
10%
$1,603
-$1,295
Citigroup Inc
439,090 sh
-326,999 sh
-43%
$1,023
-$2,539
State Of Wisconsin Investment Board
336,900 sh
 
$785
Gsa Capital Partners Llp
321,129 sh
286,428 sh
825%
$748
$587
Alliancebernstein L.P.
320,100 sh
900 sh
0%
$746
-$738
Rhumbline Advisers
309,702 sh
5,297 sh
2%
$722
-$693
Qube Research & Technologies Ltd
299,507 sh
274,669 sh
1106%
$698
$583
Mutual Of America Capital Management LLC
260,925 sh
-11,341 sh
-4%
$608
-$658
Victory Capital Management Inc
260,362 sh
223,602 sh
608%
$393
$222

Data imported from Sorrento Therapeutics Inc SEC filings. Check original filings before making any investment decision.